Iguratimod Report: Delta4 Hyper-C Case Study

Unveiling Drug Discoveries: Download Hyper-C Iguratimod Report

Dive into the groundbreaking exploration of iguratimod’s vast potential, meticulously unearthed by Delta4’s state-of-the-art Hyper-C platform. From constructing intricate molecular models to unveiling promising novel indications, our comprehensive report offers a treasure trove of insights.

Included in the report:

Introduction: Overview of Delta4's Hyper-C platform and iguratimod's background.
Molecular MoA Model: Construction of iguratimod's Mechanism of Action model, highlighting primary drug targets.
Known Disease Space: Identification of 262 directly annotated diseases/phenotypes for iguratimod.
Computational Screening: Methodology to screen against Delta4's phenotype library for potential iguratimod indications.
Result Analysis: Discovery of 59 "novel" potential indications, including the top five most promising diseases.
Case Study: In-depth focus on an identified condition as a standout novel indication.

Download Hyper-C Iguratimod Report

Play Video about Iguratimod Case Study

About Delta4

Helping Millions Of Patients With Rare Diseases By Pioneering The Treatments Of Tomorrow, Today

Delta4, an AI-enabled drug repurposing leader, empowers healthcare professionals to discover and improve treatments. Our data-driven approach combines AI and expert insights for effective indication expansion. Drug repurposing, though complex, saves time and resources in treatment development. Our platform, Hyper-C, identifies and assesses potential drug candidates. We continuously enhance our platform and algorithms to uncover promising candidates efficiently. Our dedicated team ensures high-quality service for successful drug repurposing.

Find or Expand Indications For Your Existing Drugs

Our AI-powered platform enables companies to quickly identify new therapeutic uses for existing drugs with known safety profiles and accelerate their development, approval, and commercialization.

Identify and rank disease-modifying drug targets

Hyper-C can rapidly identify drug targets which are essential for the development of safe and effective drugs. This helps to significantly reduce drug development time and cost by focusing on drug targets with the greatest potential to be effective.

Provide specific background info on a drug effect/side effect

Leveraging Hyper-C’s artificial intelligence-powered algorithms, we’re able to provide insights into how potential drug effects and side effects may interact with each other, allowing for safer and more effective treatments.

Propose prognostic and predictive protein biomarkers

With our platform, researchers, pharmaceutical companies, and clinicians can identify potential biomarkers for various diseases and medical conditions. This gives them the ability to predict disease progression, identify prognostic indicators, and even personalize treatment plans.

Download Delta4's Iguratimod Hyper-C Report

Download the report and step into the future of drug indication expansion!

Our Partners & Clients

Proud Member of Scientist.com

Streamlining Transparency and Cooperation

Scientist.com provides a unique platform where researchers and suppliers can both find each other and work together more easily. They provide a collaboration framework to streamline the typically long and tedious process of defining the terms and conditions of an agreement.
Members can work together smoothly and effortlessly by agreeing to the rules of the platform. The result is that together we can achieve the results we need faster.